Considerations for designing preclinical cancer immune nanomedicine studies.
Considerations for designing preclinical cancer immune nanomedicine studies.
复制标题
DOI：
10.1038/s41565-020-00817-9
复制
发表时间：
2021-01
影响因子：
38.3
通讯作者：
Kim BYS
中科院分区：
文献类型：
--
作者：
Jiang W;Wang Y;Wargo JA;Lang FF;Kim BYS
众所周知，免疫疗法在临床上对癌症患者有益，并且在许多情况下已成为新的护理标准。由于这一成功，人们对将纳米医学与癌症免疫疗法相结合的兴趣日益浓厚，以进一步改善临床反应和毒性特征。然而，与直接对肿瘤细胞产生细胞毒性的传统全身疗法不同，癌症免疫疗法依赖宿主的免疫系统产生杀肿瘤作用。因此，癌症免疫纳米药物的正确设计需要对可能影响宿主抗肿瘤免疫的肿瘤内在和外在因素进行额外的审查。在这里，我们重点介绍了区分癌症免疫疗法与传统细胞毒性药物的关键参数，并讨论了它们对设计临床前癌症免疫纳米医学研究的影响。我们强调，这些因素，包括肿瘤内基因组异质性、共生多样性、性二态性和生物衰老，在传统癌症纳米医学实验中很大程度上被忽视，鉴于它们在塑造人体抗肿瘤免疫反应中发挥着关键作用，应在适当的背景下仔细考虑并纳入癌症免疫纳米医学研究中。
Immunotherapy is known to be clinically beneficial for patients with cancer and has in many cases become the new standard of care. Because of this success, the interest in integrating nanomedicine with cancer immunotherapy has grown to further improve clinical response and toxicity profiles. However, unlike conventional systemic therapies, which are directly cytotoxic to tumour cells, cancer immunotherapy relies on the host’s immune system to generate tumouricidal effects. As such, proper design of cancer immune nanomedicine requires additional scrutiny of tumours’ intrinsic and extrinsic factors that may impact host antitumour immunity. Here, we highlight key parameters that differentiate cancer immunotherapy from conventional cytotoxic agents, and we discuss their implications for designing preclinical cancer immune nanomedicine studies. We emphasize that these factors, including intratumoural genomic heterogeneity, commensal diversity, sexual dimorphism, and biological aging, which were largely ignored in traditional cancer nanomedicine experiments, should be carefully considered and incorporated into cancer immune nanomedicine investigations in the proper context given their critical involvement in shaping the body’s antitumour immune responses.
登录
查看更多内容
癌症死亡率和生存中的性别差异。
DOI：
10.1158/1055-9965.epi-11-0246
发表时间：
2011-08
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Cook MB;McGlynn KA;Devesa SS;Freedman ND;Anderson WF
通讯作者：
Anderson WF
影响因子：
38.3
作者：
Faria M;Björnmalm M;Thurecht KJ;Kent SJ;Parton RG;Kavallaris M;Johnston APR;Gooding JJ;Corrie SR;Boyd BJ;Thordarson P;Whittaker AK;Stevens MM;Prestidge CA;Porter CJH;Parak WJ;Davis TP;Crampin EJ;Caruso F
通讯作者：
Caruso F
DOI：
10.1016/j.cub.2015.07.037
发表时间：
2015-08-31
期刊：
Current biology : CB
影响因子：
--
作者：
Brandt JP;Ringstad N
通讯作者：
Ringstad N
影响因子：
82.9
作者：
Andor N;Graham TA;Jansen M;Xia LC;Aktipis CA;Petritsch C;Ji HP;Maley CC
通讯作者：
Maley CC
影响因子：
16.6
作者：
Dubin K;Callahan MK;Ren B;Khanin R;Viale A;Ling L;No D;Gobourne A;Littmann E;Huttenhower C;Pamer EG;Wolchok JD
通讯作者：
Wolchok JD